DK2013236T3 - ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK - Google Patents

ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK Download PDF

Info

Publication number
DK2013236T3
DK2013236T3 DK07720099.6T DK07720099T DK2013236T3 DK 2013236 T3 DK2013236 T3 DK 2013236T3 DK 07720099 T DK07720099 T DK 07720099T DK 2013236 T3 DK2013236 T3 DK 2013236T3
Authority
DK
Denmark
Prior art keywords
alk
gly
ser
ala
antibody
Prior art date
Application number
DK07720099.6T
Other languages
Danish (da)
English (en)
Inventor
Der Maur Adrian Auf
Peter Lichtlen
Alcide Barberis
Original Assignee
Delenex Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics Ag filed Critical Delenex Therapeutics Ag
Application granted granted Critical
Publication of DK2013236T3 publication Critical patent/DK2013236T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07720099.6T 2006-04-28 2007-04-27 ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK DK2013236T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
PCT/CH2007/000202 WO2007124610A1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Publications (1)

Publication Number Publication Date
DK2013236T3 true DK2013236T3 (en) 2015-09-21

Family

ID=38515389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07720099.6T DK2013236T3 (en) 2006-04-28 2007-04-27 ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK

Country Status (16)

Country Link
US (3) US7902340B2 (enExample)
EP (2) EP2604627A1 (enExample)
JP (2) JP5431920B2 (enExample)
KR (1) KR101457228B1 (enExample)
CN (1) CN101443361B (enExample)
AU (1) AU2007246144B2 (enExample)
BR (1) BRPI0710971A2 (enExample)
CA (1) CA2650822C (enExample)
DK (1) DK2013236T3 (enExample)
ES (1) ES2547248T3 (enExample)
IL (1) IL194752A0 (enExample)
MX (1) MX2008013705A (enExample)
NZ (1) NZ572248A (enExample)
PL (1) PL2013236T3 (enExample)
RU (1) RU2460540C2 (enExample)
WO (1) WO2007124610A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007246144B2 (en) * 2006-04-28 2012-12-06 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
MX345395B (es) 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムFc二重特異性抗体
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
WO2015184231A2 (en) * 2014-05-30 2015-12-03 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
EP3341021A4 (en) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
JP7017015B2 (ja) 2015-10-13 2022-02-08 エウレカ セラピューティクス インコーポレイテッド ヒトcd19に特異的な抗体剤及びその使用
RU2767209C2 (ru) 2015-10-23 2022-03-16 Еурека Терапьютикс, Инк. Химерные конструкции антитело/т-клеточный рецептор и их применения
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
IL310182A (en) 2017-04-26 2024-03-01 Eureka Therapeutics Inc ׂ A Delaware Corp Structures of chimeric antibody/T-cell receptor and uses thereof
EP3749682B1 (en) * 2018-02-09 2025-09-24 Acceleron Pharma Inc. Treating heterotopic ossification
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
EP0938506B1 (en) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
JPH1116250A (ja) * 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
DK1242457T3 (da) * 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
DE60141518D1 (de) * 2000-06-14 2010-04-22 Univ Georgetown Pleiotrophin wachstumfaktor rezeptor alk zur behandlung von proliferativen, gefässer- und neurologischen erkrankungen
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
CN105175535A (zh) 2002-05-22 2015-12-23 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
AU2005272920B2 (en) 2004-08-10 2011-05-12 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
AU2007246144B2 (en) * 2006-04-28 2012-12-06 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Also Published As

Publication number Publication date
CN101443361A (zh) 2009-05-27
EP2013236B1 (en) 2015-06-17
AU2007246144A1 (en) 2007-11-08
JP5431920B2 (ja) 2014-03-05
CA2650822C (en) 2017-03-14
RU2460540C2 (ru) 2012-09-10
US8945563B2 (en) 2015-02-03
KR20080113261A (ko) 2008-12-29
EP2013236A1 (en) 2009-01-14
US7902340B2 (en) 2011-03-08
EP2604627A1 (en) 2013-06-19
IL194752A0 (en) 2011-08-01
AU2007246144B2 (en) 2012-12-06
JP2013226144A (ja) 2013-11-07
MX2008013705A (es) 2008-11-06
CA2650822A1 (en) 2007-11-08
WO2007124610A1 (en) 2007-11-08
JP2009535021A (ja) 2009-10-01
US20110159008A1 (en) 2011-06-30
HK1124619A1 (en) 2009-07-17
US20080118512A1 (en) 2008-05-22
RU2008146922A (ru) 2010-06-10
CN101443361B (zh) 2015-08-19
JP5911821B2 (ja) 2016-04-27
NZ572248A (en) 2011-08-26
US20150203829A1 (en) 2015-07-23
KR101457228B1 (ko) 2014-11-04
US9512411B2 (en) 2016-12-06
ES2547248T3 (es) 2015-10-02
PL2013236T3 (pl) 2015-12-31
BRPI0710971A2 (pt) 2011-05-31

Similar Documents

Publication Publication Date Title
DK2013236T3 (en) ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK
CN109265550B (zh) Bcma抗体、嵌合抗原受体和药物
KR102427334B1 (ko) 키메라 항원 및 t 세포 수용체 및 사용 방법
CN112125974B (zh) 靶向bcma蛋白的抗体、嵌合抗原受体和药物
AU2017240150C1 (en) BCMA binding molecules and methods of use thereof
CN112500480B (zh) 针对新型冠状病毒的纳米抗体及其应用
KR20210094509A (ko) 재조합 점액종 바이러스 및 이의 용도
KR20140093922A (ko) Agr2 차단 항체 및 그의 용도
KR20050119120A (ko) 인간 ⅰl-21 수용체에 대한 항체 및 그것의 용도
HUE027358T2 (en) Anti-mesothelin antibodies and their applications
CN111825766B (zh) 抗il-4r单域抗体及其应用
WO2008131575A2 (en) Anti-alk antibodies suitable for treating metastatic cancers or tumors
CN112245578B (zh) 一种covid-19病毒预防性疫苗及其制备方法
TW202237642A (zh) 對冠狀病毒具有特異性的抗原結合多肽及其用途
AU2012244351B2 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
HK1124619B (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
Marshall Towards cancer immunotherapy: Analysis of a tumor targeting antibody and engineering of a novel fusion protein to activate cytotoxic T cells